NSE filing, NSE: BETA. Summary written from the filing by ALFA Finder's alert engine.
Beta Drugs Ltd: key numbers
- Share price
- ₹1,798.40
- Market cap
- ₹1,994 Cr
- Revenue (annual)
- ₹384.8 Cr
- Net profit (annual)
- ₹41.48 Cr
- P/E (TTM)
- 38.4×Sector 45.9×
- Promoter holding
- 58.91%-0.19% QoQ
- FII holding
- 1.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beta Drugs Ltd
All →Beta Drugs Other Announcement
Beta Drugs Limited submitted its quarterly Statement of Deviation or Variation for the preferential issue proceeds, confirming no deviation from the stated objects.
Beta Drugs Earnings Call Transcript: Key Takeaways
Management projects a 20-25% growth trajectory despite Q2 bottlenecks. Recent acquisitions and niche oncology focus underpin expansion strategy.
- Call
- Guides 25% growth
Beta Drugs Investor Presentation: Key Takeaways
Beta Drugs reported H1 FY27 revenue of INR 263 Cr with EBITDA margins expanding to 23.2%. The firm is transitioning from a CMO to a branded specialty oncology powerhouse.
Beta Drugs Q2 FY27 Results: Net Profit ₹185,507,075 Cr, Up 51.8% YoY
Beta Drugs Ltd reported revenue from operations of ₹1,374,887,594 Cr (+33.0% YoY) and net profit of ₹185,507,075 Cr (+51.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹185,507,075 Cr · +51.8% YoY
Beta Drugs Board Meeting Date
Beta Drugs Limited notified the exchange of a board meeting scheduled for 22-Oct-2026 to consider quarterly financial results. The trading window closure was also intimated.
Beta Drugs Annual General Meeting
Beta Drugs Limited conducted its 21st Annual General Meeting on September 30, 2026. Shareholders considered resolutions including financial statement adoption, director re-appointments, and auditor ratification.
Other management change announcements
All →REC Management Change
REC Limited intimated that Executive Director J.K. Nayak ceased to hold that role effective 30 October 2026. He was appointed Chairman & Managing Director of IREDA.
Himadri Speciality Chemical Management Change
Himadri Speciality Chemical's board revised its senior management list following organisational restructuring. Six personnel are listed, including the CFO and Company Secretary.
HMT Management Change
HMT Ltd intimated the resignation of Aparna R, Assistant General Manager (F&A), who ceases as CFO and KMP effective close of business on October 30, 2026. Her resignation letter is attached.
Share India Securities Management Change
Share India Securities appointed Krishan Singh Barguzar as Non-Executive Independent Director for 36 months, effective 30 October 2026. He is a former SBI Chief General Manager.
Indian Renewable Energy Development Agency Management Change
IREDA appointed Jatin Kumar Nayak as CMD effective October 30, 2026. Dr. Bijay Kumar Mohanty ceased to hold the additional CMD charge that day.
Kwality Wall's (India) Management Change
Kwality Wall's appointed Tahir Toloy Tanridagli as MD and CEO for three years from November 1, 2026. Vivek Sarbhai ceases as Senior Management Personnel from October 31.
- Execution
- 3 years (1 November 2026 to 31 October 2029)